While targeting the initial gene/protein defect in NPC1 may prove elusive for the time being, the presence of many different downstream therapeutic targets would suggest that a combination of central and peripheral therapies might play an important role in the management of symptoms for patients with NP-C, and could potentially have synergistic effects. Here, NPC1 is linked to nasopharyngeal carcinoma.